Age-related hearing loss (ARHL) or presbycusis is the gradual loss of hearing sensitivity with age. It affects one in three people between the ages of 65 to 74 and nearly half of people over 75 in the USA (National Institute on Deafness and Other Communication Disorders). Since the exact biological causes and mechanisms of ARHL are not completely known [1], preclinical and basic science research has been crucial for informing the current understanding of ARHL through physiological [2], anatomical [3], behavioral [4], and genetic [5] studies. ARHL has clinical associations with cognitive decline [6], social isolation [7], and memory loss [8], as well as increased risk of falls [9], hospitalization [10], and mortality [11], which underscore the importance of preclinical and basic science investigations of this condition. There are well-known differences in the trajectory of ARHL for men and women; studies indicate that men experience a faster decline in hearing ability than women [12, 13].

Using animals in preclinical and basic science research provides a unique advantage in understanding the effects of age on hearing loss since the auditory environment and other potentially interacting factors can be carefully controlled. However, the number of preclinical studies that explicitly investigated the effects of sex-based differences on AHRL is relatively small [14–20], and further investigations are needed for a more comprehensive understanding. In C57BL/6 mice, females demonstrated accelerated increases in auditory brainstem response (ABR) thresholds with age compared to males [19, 20]. In another study, young male and female CBA mice (substrain unspecified) demonstrated similar distortion product otoacoustic emissions (DPOAEs), but females demonstrated higher premenopausal DPOAE levels, which declined postmenopause. Old CBA females also had lower ABR thresholds than old CBA males [18]. Studies investigating the protective effects of exposure to an augmented acoustic environment against ARHL have also shown differences in treatment effectiveness between males and females [15, 16, 20].

Basic and preclinical research has clear and direct implications for translational research and clinical outcomes [21]. Therefore, an understanding of sex as a biological variable and its effects on preclinical research, and here particularly on ARHL research, is important for informing treatment and prevention strategies. The National Institutes of Health (NIH) has required the inclusion of men and women in NIH-funded clinical research since 1993 through the Revitalization Act, but the inclusion of both sexes in basic and preclinical research was not required by the NIH until January of 2016 [22]. This is significant as NIH-funded basic research contributes substantially to drug development [23], and studies have demonstrated that mammalian traits in both wildtypes and mutants are influenced by sex [24].

Other fields have addressed the issue of sex bias in preclinical and basic research including dermatology [25], cardiology [26], surgery, [27], and general neuroscience [28, 29]. However, sex bias has only been addressed in one study with a focus on auditory neuroscience that identified sex bias in preclinical and basic noise-induced hearing loss (NIHL) research [30]. In the present study, the representation of sex as a biological variable in basic and preclinical studies of ARHL was evaluated for the 10-year period from January 2006 to December 2015 to understand sex bias in studies of ARHL prior to the NIH mandate.

This study demonstrates sex bias in basic and preclinical ARHL research. Thirteen percent of studies did not report the total number of animals used. About two thirds of papers reported the sex of animals used, and of studies that reported sex, males only were used over 2.5 times more than females only. For studies that reported the sex and total number of animals used, about two thirds of animals used were male and one third were female. There were a nearly equal number of US-based and international-based studies, with about an equal proportion of US and international studies reporting sex. The proportion of studies including both sexes was over two times greater for US-based studies compared to international-based studies. Five times as many papers did not report sex-based results compared to those that did, and of those that did, US-based papers were three times more likely to do so than international-based papers.

Over the 10-year period of 2006 to 2015, the proportion of studies using both sexes of animals decreased by 40%, and whereas the proportion of studies including males only increased nearly twofold, the number of females only increased over threefold. Overall, the number of manuscripts on ARHL increased from 2006 to 2015, but there was a nearly 40% decrease in the number of papers discussing sex-based results. Compared to the previous sex bias study on noise-induced hearing loss (NIHL), this study finds a lower proportion of studies using males only at 34% (compared to 61%) [30]. Additionally, in studies reporting sex and number of animals used, 67% of all animals used in ARHL studies were males, as opposed to the 81% found in the study on NIHL [30].

Some investigators cited increased variability related to estrogen cycles to justify the exclusion of females from ARHL studies [31], yet it has been found that the estrous cycle is not generally an influential factor in differences in variability between male and female rodents [32]. When estrous cycle does affect hearing outcomes, studying these effects will improve our understanding of ARHL and could help identify potential new treatments. For example, studying hearing in women and female animals has led to the recognition of estrogen as a possible protective agent against hearing loss [33].

Sex bias is prevalent in basic and preclinical ARHL research. The inclusion of both males and females in basic and preclinical ARHL research is critical for translational and clinical research outcomes. If only one sex is tested, it is impossible to know which results will generalize to the other sex. By including both sexes in preclinical research, it should be possible to avoid sex-specific issues later in drug development and clinical studies, such as ineffectiveness or adverse side effects. When treatments and therapies move to a clinical level, it is important to be able to predict any sex-specific outcomes for better personalization of healthcare treatment. Including sex as a biological variable in basic and preclinical research may reveal other mechanisms of sex differences in ARHL and hasten translation to viable prevention and treatment options.